In the current market session, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock price is at $780.00, after a 0.95% drop. However, over the past month, the company's stock spiked by 1.61%, and in the past year, by 12.75%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.
<img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Past Year Chart" width="600" height="600" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_0.png"/>
<h3>Comparing Regeneron Pharmaceuticals P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 76.09 in the Biotechnology industry, Regeneron Pharmaceuticals Inc. has a lower P/E ratio of 18.48. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 
<img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Guage" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_1.png"/>
In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

REGN

IBBQ

ARKG

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock is currently priced at $780.00, reflecting a 0.95% drop. Over the past month, the stock has increased by 1.61% and by 12.75% over the past year. The company's P/E ratio stands at 18.48, significantly lower than the Biotechnology industry average of 76.09, suggesting potential undervaluation or lower growth expectations. Investors are advised to consider the P/E ratio alongside other financial metrics and qualitative factors for informed decision-making.

P/E Ratio Insights for Regeneron Pharmaceuticals